Spectrum's belinostat shrinks tumors in blood cancer study

12/26/2012 | Reuters

Spectrum Pharmaceuticals' investigational drug belinostat achieved the primary goal of shrinking tumors in a Phase II trial involving patients with relapsed/refractory peripheral T-cell lymphoma who had not responded to at least one previous treatment. The firm plans to submit the drug, which has fast-track and orphan-drug status, for marketing approval by the middle of next year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care